Li Xin

Ms. Li Xin


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2026 in AI
Verified
Journal Article
Open access
PDF file
WWWang Wang
Wang Wang
XXXiaoxu XU
Xiaoxu XU
LXLi Xin
Li Xin
LMLuochenxi Mou
Luochenxi Mou
CCCan Cui
Can Cui
Ning ZhangNing Zhang
Ning Zhang
Sarcopenia is a progressive, age-related skeletal muscle disorder that serves as a driver of frailty, falls, and mortality in older adults. Despite the recent paradigm shift introduced by the latest sarcopenia consensus, which emphasizes early, proactive detection, sarcopenia cases frequently evade traditional screening due to inherent diagnostic bottlenecks and resource limitations. Artificial intelligence has emerged as a transformative solution to dismantle these barriers across the entire continuum of sarcopenia care. This review explores the rapid evolution of artificial intelligence, beginning with automated opportunistic screening that extracts prognostic musculoskeletal data from routine imaging and electronic health records, advancing toward high-precision multimodal assessment architectures. Beyond initial assessment, artificial intelligence is actively restructuring longitudinal care by the integration of ubiquitous wearables, Large Language Models, and computer vision, enabling dynamic exercise prescriptions and real-time kinematic postural correction for sarcopenia rehabilitation. Realizing this potential requires the medical community to confront urgent clinical barriers, including multi-center validation, semantic interoperability, health economic justification, and the strict preservation of human-centric ethics. By addressing these challenges, this review provides a definitive roadmap for embedding artificial intelligence across the entire sarcopenia care pathway, transforming isolated instances of opportunistic screening into a unified ecosystem for intelligent, proactive rehabilitation.

15 September 2026 in Antioxidants
Verified
Journal Article
Open access
PDF file
LXLi Xin
Li Xin
KZKe Zhou
Ke Zhou
RWRonald Man Yeung Wong
Ronald Man Yeung Wong
WCWing Hoi Cheung
Wing Hoi Cheung
CCCan Cui
Can Cui
Oxidative stress contributes to aging-related muscle decline, but antioxidant interventions may affect functional and structural outcomes differently. This systematic review synthesized clinical, animal, and cellular evidence across clinically defined sarcopenia and broader models of aging-related muscle decline. PubMed, Embase, Web of Science, and Cochrane Central Register of Controlled Trials (CENTRAL) were searched through 11 July 2026. Eligible studies tested antioxidant interventions in older adults or aging-related preclinical models and were appraised using the Cochrane Risk of Bias 2 (RoB 2) tool, a modified Systematic Review Centre for Laboratory animal Experimentation (SYRCLE) risk-of-bias tool, and a modified in vitro checklist. Forty-four publications were included: eight clinical trials, 26 animal datasets, and 18 cellular datasets, with eight publications contributing both animal and cellular evidence. Comparative clinical benefits were reported primarily for strength or power (7/8 studies), with less support for physical performance (2/6 studies assessing this domain) or body composition-related muscle quantity (2/8 studies). Selected preclinical studies likewise showed functional gains without parallel structural improvement, although effects varied by model and intervention. Preclinical findings implicated antioxidant defense, mitochondrial maintenance, inflammation, and proteostasis, but most pathway evidence was associative and direct experimental validation was limited. Clinical evidence was further constrained by small samples, short interventions, combined nutritional or exercise co-interventions, and heterogeneous outcomes. Current evidence does not support a consistent increase in muscle quantity with antioxidant interventions. The observed pattern appears context dependent and requires confirmation in adequately powered, phenotype-stratified trials assessing muscle strength, physical performance, muscle quantity, and mechanistic endpoints.